182 related articles for article (PubMed ID: 35047751)
21. Circulating insulin-like growth factor-I and binding protein-3 and risk of prostate cancer.
Severi G; Morris HA; MacInnis RJ; English DR; Tilley WD; Hopper JL; Boyle P; Giles GG
Cancer Epidemiol Biomarkers Prev; 2006 Jun; 15(6):1137-41. PubMed ID: 16775172
[TBL] [Abstract][Full Text] [Related]
22. Circulating free insulin-like growth factor (IGF)-I, total IGF-I, and IGF binding protein-3 levels do not predict the future risk to develop prostate cancer: results of a case-control study involving 201 patients within a population-based screening with a 4-year interval.
Janssen JA; Wildhagen MF; Ito K; Blijenberg BG; Van Schaik RH; Roobol MJ; Pols HA; Lamberts SW; Schröder FH
J Clin Endocrinol Metab; 2004 Sep; 89(9):4391-6. PubMed ID: 15356036
[TBL] [Abstract][Full Text] [Related]
23. Serum levels of insulin-like growth factor I (IGF-I), IGF-II, IGF-binding protein-3, and prostate-specific antigen as predictors of clinical prostate cancer.
Harman SM; Metter EJ; Blackman MR; Landis PK; Carter HB;
J Clin Endocrinol Metab; 2000 Nov; 85(11):4258-65. PubMed ID: 11095464
[TBL] [Abstract][Full Text] [Related]
24. Serum IGF-I, IGF-II, IGFBP-3, and IGF-I/IGFBP-3 molar ratio and risk of pancreatic cancer in the prostate, lung, colorectal, and ovarian cancer screening trial.
Douglas JB; Silverman DT; Pollak MN; Tao Y; Soliman AS; Stolzenberg-Solomon RZ
Cancer Epidemiol Biomarkers Prev; 2010 Sep; 19(9):2298-306. PubMed ID: 20699371
[TBL] [Abstract][Full Text] [Related]
25. Serum insulin-like growth factor I: tumor marker or etiologic factor? A prospective study of prostate cancer among Finnish men.
Woodson K; Tangrea JA; Pollak M; Copeland TD; Taylor PR; Virtamo J; Albanes D
Cancer Res; 2003 Jul; 63(14):3991-4. PubMed ID: 12873996
[TBL] [Abstract][Full Text] [Related]
26. Pregnancy associated plasma protein-A2 (PAPP-A2) and stanniocalcin-2 (STC2) but not PAPP-A are associated with circulating total IGF-1 in a human adult population.
Nimptsch K; Aydin EE; Chavarria RFR; Janke J; Poy MN; Oxvig C; Steinbrecher A; Pischon T
Sci Rep; 2024 Jan; 14(1):1770. PubMed ID: 38245583
[TBL] [Abstract][Full Text] [Related]
27. Plasma levels of IGF-1, IGF-2, and IGFBP-3 in white and African-American men at increased risk of prostate cancer.
Winter DL; Hanlon AL; Raysor SL; Watkins-Bruner D; Pinover WH; Hanks GE; Tricoli JV
Urology; 2001 Oct; 58(4):614-8. PubMed ID: 11597555
[TBL] [Abstract][Full Text] [Related]
28. Insulin-like growth factors, their binding proteins, and prostate cancer risk: analysis of individual patient data from 12 prospective studies.
Roddam AW; Allen NE; Appleby P; Key TJ; Ferrucci L; Carter HB; Metter EJ; Chen C; Weiss NS; Fitzpatrick A; Hsing AW; Lacey JV; Helzlsouer K; Rinaldi S; Riboli E; Kaaks R; Janssen JA; Wildhagen MF; Schröder FH; Platz EA; Pollak M; Giovannucci E; Schaefer C; Quesenberry CP; Vogelman JH; Severi G; English DR; Giles GG; Stattin P; Hallmans G; Johansson M; Chan JM; Gann P; Oliver SE; Holly JM; Donovan J; Meyer F; Bairati I; Galan P
Ann Intern Med; 2008 Oct; 149(7):461-71, W83-8. PubMed ID: 18838726
[TBL] [Abstract][Full Text] [Related]
29. Insulin-like growth factor-I concentration and risk of prostate cancer: results from the European Prospective Investigation into Cancer and Nutrition.
Price AJ; Allen NE; Appleby PN; Crowe FL; Travis RC; Tipper SJ; Overvad K; Grønbæk H; Tjønneland A; Johnsen NF; Rinaldi S; Kaaks R; Lukanova A; Boeing H; Aleksandrova K; Trichopoulou A; Trichopoulos D; Andarakis G; Palli D; Krogh V; Tumino R; Sacerdote C; Bueno-de-Mesquita HB; Argüelles MV; Sánchez MJ; Chirlaque MD; Barricarte A; Larrañaga N; González CA; Stattin P; Johansson M; Khaw KT; Wareham N; Gunter M; Riboli E; Key T
Cancer Epidemiol Biomarkers Prev; 2012 Sep; 21(9):1531-41. PubMed ID: 22761305
[TBL] [Abstract][Full Text] [Related]
30. Levels of insulin-like growth factor I (IGF-I) and IGF binding proteins 2 and 3 in serial postoperative serum samples and risk of prostate cancer recurrence.
Yu H; Nicar MR; Shi R; Berkel HJ; Nam R; Trachtenberg J; Diamandis EP
Urology; 2001 Mar; 57(3):471-5. PubMed ID: 11248622
[TBL] [Abstract][Full Text] [Related]
31. Milk intake, circulating levels of insulin-like growth factor-I, and risk of colorectal cancer in men.
Ma J; Giovannucci E; Pollak M; Chan JM; Gaziano JM; Willett W; Stampfer MJ
J Natl Cancer Inst; 2001 Sep; 93(17):1330-6. PubMed ID: 11535708
[TBL] [Abstract][Full Text] [Related]
32. Insulin-like growth factor I (IGF-I) and IGF-binding protein-3 in benign prostatic hyperplasia and prostate cancer.
Khosravi J; Diamandi A; Mistry J; Scorilas A
J Clin Endocrinol Metab; 2001 Feb; 86(2):694-9. PubMed ID: 11158033
[TBL] [Abstract][Full Text] [Related]
33. Prospective study of colorectal cancer risk in men and plasma levels of insulin-like growth factor (IGF)-I and IGF-binding protein-3.
Ma J; Pollak MN; Giovannucci E; Chan JM; Tao Y; Hennekens CH; Stampfer MJ
J Natl Cancer Inst; 1999 Apr; 91(7):620-5. PubMed ID: 10203281
[TBL] [Abstract][Full Text] [Related]
34. Plasma levels of insulin-like growth factor-I and lung cancer risk: a case-control analysis.
Yu H; Spitz MR; Mistry J; Gu J; Hong WK; Wu X
J Natl Cancer Inst; 1999 Jan; 91(2):151-6. PubMed ID: 9923856
[TBL] [Abstract][Full Text] [Related]
35. Metabolic improvement after gastric bypass correlates with changes in IGF-regulatory proteins stanniocalcin-2 and IGFBP-4.
Hjortebjerg R; Bojsen-Møller KN; Søeby M; Oxvig C; Madsbad S; Frystyk J
Metabolism; 2021 Nov; 124():154886. PubMed ID: 34506805
[TBL] [Abstract][Full Text] [Related]
36. Insulin-like growth factor I is not a useful marker of prostate cancer in men with elevated levels of prostate-specific antigen.
Finne P; Auvinen A; Koistinen H; Zhang WM; Määttänen L; Rannikko S; Tammela T; Seppälä M; Hakama M; Stenman UH
J Clin Endocrinol Metab; 2000 Aug; 85(8):2744-7. PubMed ID: 10946875
[TBL] [Abstract][Full Text] [Related]
37. Insulin-like growth factor pathway genetic polymorphisms, circulating IGF1 and IGFBP3, and prostate cancer survival.
Cao Y; Lindström S; Schumacher F; Stevens VL; Albanes D; Berndt S; Boeing H; Bueno-de-Mesquita HB; Canzian F; Chamosa S; Chanock SJ; Diver WR; Gapstur SM; Gaziano JM; Giovannucci EL; Haiman CA; Henderson B; Johansson M; Le Marchand L; Palli D; Rosner B; Siddiq A; Stampfer M; Stram DO; Tamimi R; Travis RC; Trichopoulos D; Willett WC; Yeager M; Kraft P; Hsing AW; Pollak M; Lin X; Ma J
J Natl Cancer Inst; 2014 Jun; 106(6):dju085. PubMed ID: 24824313
[TBL] [Abstract][Full Text] [Related]
38. Serum insulin, glucose, indices of insulin resistance, and risk of prostate cancer.
Albanes D; Weinstein SJ; Wright ME; Männistö S; Limburg PJ; Snyder K; Virtamo J
J Natl Cancer Inst; 2009 Sep; 101(18):1272-9. PubMed ID: 19700655
[TBL] [Abstract][Full Text] [Related]
39. Protein expression of PTEN, insulin-like growth factor I receptor (IGF-IR), and lethal prostate cancer: a prospective study.
Zu K; Martin NE; Fiorentino M; Flavin R; Lis RT; Sinnott JA; Finn S; Penney KL; Ma J; Fazli L; Gleave ME; Bismar TA; Stampfer MJ; Pollak MN; Loda M; Mucci LA; Giovannucci E
Cancer Epidemiol Biomarkers Prev; 2013 Nov; 22(11):1984-93. PubMed ID: 23983239
[TBL] [Abstract][Full Text] [Related]
40. Serum C-peptide, insulin-like growth factor (IGF)-I, IGF-binding proteins, and colorectal cancer risk in women.
Kaaks R; Toniolo P; Akhmedkhanov A; Lukanova A; Biessy C; Dechaud H; Rinaldi S; Zeleniuch-Jacquotte A; Shore RE; Riboli E
J Natl Cancer Inst; 2000 Oct; 92(19):1592-600. PubMed ID: 11018095
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
